Palvella Adds Rare Disease Commercial Leader Ahead of Potential QTORIN Launch
Event summary
- Jennifer J. McDonough appointed Senior Vice President of Market Access and Patient Services at Palvella Therapeutics.
- McDonough previously led the successful U.S. launch of Krystal Biotech's VYJUVEK®, growing sales to $389 million in 2025.
- Palvella prepares for a potential near-term U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations.
- McDonough brings over 25 years of experience in rare disease commercialization and patient access strategy.
The big picture
Palvella's appointment of Jennifer J. McDonough underscores the strategic importance of building robust commercial capabilities ahead of its potential QTORIN™ launch. The move reflects a broader industry trend where biopharmaceutical companies prioritize market access and patient services to ensure successful product introductions in competitive rare disease markets. With McDonough's track record of driving significant revenue growth for Krystal Biotech's VYJUVEK®, Palvella aims to position itself as a leader in the treatment of serious, rare skin diseases and vascular malformations.
What we're watching
- Launch Readiness
- How Palvella's new market access and patient services infrastructure will impact the timely launch of QTORIN™ rapamycin.
- Revenue Trajectory
- Whether McDonough can replicate her success with VYJUVEK® in driving rapid uptake for Palvella's lead product.
- Pipeline Development
- The pace at which Palvella advances its pipeline of therapies for serious, rare skin diseases and vascular malformations.